Maxson releases FY2026 Q3 financial report, outperforming expectations and boosting stock activity

Economic Observer Network

Mackson released its fiscal third-quarter financial report for 2026 (ending December 31, 2025) on February 4, 2026. According to the financial data, quarterly operating revenue was $106.158 billion, an increase of 11.40% year-over-year; net profit attributable to shareholders was $1.186 billion, up 34.93% year-over-year; net profit margin was 1.12%. The company also raised its full-year earnings per share guidance, reflecting confidence in business growth. The oncology and multi-specialty segments performed strongly, with revenue increasing 31.5% year-over-year, becoming a key growth engine.

Institutional Views

Several Wall Street institutions recently updated their ratings for Mackson. TD Cowen maintained a buy rating on February 5, 2026, and raised its target price from $1,000 to $1,012. Institutions such as Wells Fargo, Evercore, Mizuho Securities, and Baird adjusted their target prices on February 6, with ranges from $885 to $1,000, with Evercore maintaining the highest target of $1,000. The current average target price among institutions is $980.47, indicating potential upside compared to the latest stock price.

Recent Stock Performance

Over the past 7 days, Mackson’s stock price has experienced significant volatility. On February 5, 2026, the stock surged 16.52% in a single day to $957.80, with a trading volume of $2.135 billion, reflecting positive market reaction to the earnings report. On February 6, the stock slightly declined 0.95%, but trading volume remained high at $1.128 billion. On February 9, the stock rebounded 1.44% to $962.32. On February 10, amid broader market risk aversion, the stock pulled back 2.82% to $935.21. The total increase over the past five days is 9.88%, and since the beginning of the year, the stock has risen 14.01%.

Recent Events

Mackson’s fiscal third-quarter performance announcement for 2026 has become a key focus, with multiple institutions updating their ratings, jointly driving active trading. Global risk aversion (such as declines in tech stocks and cryptocurrencies) has had limited impact on the healthcare sector, as Mackson’s steady performance has helped it resist declines.

The above content is compiled from publicly available information and does not constitute investment advice.